SmithKline Paxil "Late Listed" Patents Questioned By Apotex
Executive Summary
FDA should de-list from the Orange Book two "late-listed" patents to SmithKline Beecham's Paxil NDA, Apotex requested in a Feb. 3 citizen petition to FDA.
You may also be interested in...
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."
Bristol BuSpar Metabolite Data Requested By FDA Before Final Patent Listing
FDA is requesting additional information from Bristol-Myers Squibb on the company's BuSpar (buspirone) metabolite patent before permanently listing it in the "Orange Book."
SB Paxil Exclusivity Defense: Synthon Files NDA For Paroxetine Mesylate
SmithKline Beecham could face competition to its antidepressant Paxil in the U.S. from an NDAed version of a different salt of paroxetine filed by Synthon.